Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 239-251

  Gallant, Jean Nicolas ^a   Allen, Joshua E ^a   Smith, Charles D ^b   Dicker, David T ^a   Wang, Wenge ^a   Dolloff, Nathan G ^a   Navaraj, Arunasalam ^a   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

5 FU; Colorectal cancer; Quinacrine; Sorafenib

Indexed keywords

FLUOROURACIL; K RAS PROTEIN; MEPACRINE; PROTEIN P53; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN GEL BLOT ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MUTATION; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; QUINACRINE; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79961231807     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.17034     Document Type: Article

References (42)

1. Wallace DJ. The use of quinacrine (atabrine) in rheumatic diseases: A reexamination. Semin Arthritis Rheum 1989; 18:282-96. PMID:2658071 doi:10.1016/0049-0172(89)90050-4
2. Gardner TB, Hill DR. Treatment of giardisis. Clin Microbiol Rev 2001; 14:114-28. PMID:11148005 doi:10.1128/CMR.14.1.114-128.2001
3. Hieu DT, Vinh DQ, Tan DN, Tan TT, Nguyet PT, Than P. 31781 cases of non-surgical female sterilisation with quinacrine pellets in Vietnam. Lancet 1993; 342:213-7. PMID:8100933 doi:10.1016/0140-6736(93)92302-A
4. Collinge J, Gorhama M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8:334-44. PMID:19278902 doi:10.1016/S1474-4422(09)70049-3
5. Vassey JW, Edmonds J, Irvin JL, Green JA, Irvin EM. Studies on the administration of quinacrine to tumor-bearing mice. Cancer Res 1955; 15:573-8. PMID:13261076
6. Borja ER, Pugh RP. Single-dose quinacrine (atabrine) and thoracostomy in the control of pleural effusions in patients with neoplastic diseases. Cancer 1973; 31:899-902. PMID:4706055 doi:10.1002/1097-0142(197304)31:4⟨899:: AID-CNCR2820310421⟩3.0.CO;2-2
7. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, et al. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways. Oncogene 2009; 28:1151-61. PMID:19137016 doi:10.1038/onc.2008.460
8. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-10. PMID:10617466 doi:10.1126/science.286.5449.2507
9. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, et al. Acridine derivatives activate p53 and induce tumor cell death through bax. Cancer Biol Ther 2005; 4:893-8. PMID:16177561 doi:10.4161/cbt.4.8.2134
10. Wang W, Katz KI, Dolloff NG, Abdulghani JA, Abdulghani JE, Allen DT, et al. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutics. Cancer Biol Ther 2011; 12: In press.
11. Youle RJ, Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59. PMID:18097445 doi:10.1038/nrm2308
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90. PMID:21296855 doi:10.3322/caac. 20107
13. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134:1296-310. PMID:18471507 doi:10.1053/j.gastro.2008.02. 098
14. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102:17448-53. PMID:16287968 doi:10.1073/pnas.0508888102
15. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 2010; 285:19162-72. PMID:20424169 doi:10.1074/jbc.M109.091645
16. Lerman LS. The structure of the DNA-acridine complex. Proc Natl Acad Sci USA 1963; 49:94-102. PMID:13929834 doi:10.1073/pnas.49.1.94
17. Orzáez M, Mondragón L, García-Jareño A, Mosulén S, Pineda-Lucena A, Pérez-Paya E. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL. Bioorg Med Chem Lett 2009; 19:1592-5. PMID:19237284 doi:10.1016/j.bmcl.2009.02.020
18. Ehsanian R, Van Waes C, Feller SM. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011; 9: In press. PMID:21569639 doi:10.1186/1478-811X-9-13
19. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68. PMID:9488723 doi:10.1074/jbc.273.10.5858
20. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997; 75:337-49. PMID:9493956 doi:10.1139/o97-043
21. Luo J-L, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005; 115:2625-32. PMID:16200195 doi:10.1172/JCI26322
22. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated g(1) arrest and apoptosis. Cancer Res 1994; 54:1169-74. PMID:8118801
23. Myatt SS, Lam EW-F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7:847-59. PMID:17943136 doi:10.1038/nrc2223
24. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. P27(kip1): A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154:313-23. PMID:10027389 doi:10.1016/S0002-9440(10)65277-7
25. Hu MC-T, Lee D-F, Xia W, Golfman LS, Ou-Yang F, Yang J-Y, et al. IκB Kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37. PMID:15084260 doi:10.1016/S0092-8674(04)00302-2
26. de Souza PL, Castillo M, Myers CE. Enhancement of paclitaxel activity against hormone-refractory prostate in vitro and in vivo by quinacrine. Br J Cancer 1997; 75:1593-600. PMID:9184173 doi:10.1038/bjc.1997.272
27. Friedman J, Nottigham L, Duggal P, Pernas FG, Yan B, Yang XP, et al. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 2007; 13:6568-78. PMID:18006756 doi:10.1158/1078-0432.CCR-07-1591
28. Guo C, Stark GR. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-κB. Proc Natl Acad Sci USA 2011; 108:7968-73. PMID:21518868 doi:10.1073/pnas.1105369108
29. Illanes J, Dabancens A, Acuña O, Fuenzalida M, Guerrero A, Lopez C, et al. Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse. Biol Res 2002; 35:339-45. PMID:12462986 doi:10.4067/S0716- 97602002000300008
30. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, et al. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009; 15:2248-58. PMID:19276252 doi:10.1158/1078-0432.CCR-08-1383
31. Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5. PMID:16618717 doi:10.1158/0008-5472.CAN-06-0191
32. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-74. PMID:21376230 doi:10.1016/j.cell.2011.02.013
33. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: A gateway to TRAIL sensitization. Cancer Res 2008; 68:2062-4. PMID:18381408 doi:10.1158/0008-5472.CAN-07-6278
34. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12:66-80. PMID:17613437 doi:10.1016/j.ccr.2007.05.006
35. Snow GA, Hurst EW. The distribution of mepacrine in the organs of animal species, and in the components of liver cells. Br J Pharmacol Chemother 1956; 11:209-14. PMID:13329341
36. Huang Y, Okochi H, May BC, Legname G, Prusiner SB, Benet LZ, et al. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 2006; 34:1136-44. PMID:16581945 doi:10.1124/dmd.105.008664
37. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastastic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 1986; 150:195-203. PMID:3806280 doi:10.1002/path.1711500308
38. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007; 25:180-6. PMID:17210937 doi:10.1200/JCO.2006.09.6081
39. Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007; 66:815-7. PMID:17204564 doi:10.1136/ard.2006.067777
40. Hamelin R, Laurent-Puig P. p53 et cancers colorecteaux. Pathol Biol (Paris) 1997; 45:876-81. PMID:9769952
41. Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2003; 2:196-202. PMID:12750563 doi:10.4161/cbt.2.2.347
42. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81. PMID:16968952 doi:10.1124/pr.58.3.10